On December 19, 2023, Nathaniel S. Gardiner, age 70, Senior Vice President and General Counsel of Enanta Pharmaceuticals, Inc. announced his intention to retire on or before March 31, 2024. Enanta expects to enter into an agreement with Mr. Gardiner to provide consulting services for up to one year after his retirement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.37 USD | -0.88% | -7.13% | +31.46% |
Feb. 09 | Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating | MT |
Feb. 07 | Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.46% | 262M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ENTA Stock
- News Enanta Pharmaceuticals, Inc.
- Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024